Hospital

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

New research links long COVID taste loss to impaired sweet-bitter-umami signaling, guiding pharmacists on nutrition risks and emerging therapies.

Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

A new 4-pillar framework blends AI, real-time PDMP data, and social determinants of health to spot opioid misuse earlier and reduce overdoses.

After transitioning iron sucrose 200 mg from an infusion to intravenous push, the incidence of discordance and infusion reactions were not statistically different.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.